Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment
Victoria C Yan, Florian L Muller, Victoria C Yan, Florian L Muller
Abstract
While remdesivir has garnered much hope for its moderate anti-Covid-19 effects, its parent nucleoside, GS-441524, has been overlooked. Pharmacokinetic analysis of remdesivir evidences premature serum hydrolysis to GS-441524; GS-441524 is the predominant metabolite reaching the lungs. With its synthetic simplicity and in vivo efficacy in the veterinary setting, we contend that GS-441524 is superior to remdesivir for Covid-19 treatment.
Conflict of interest statement
The authors declare no competing financial interest.
Copyright © 2020 American Chemical Society.
Figures
References
- Cohen E.; Azad A.. The US Government’s Supply of Covid-19 Drug Remdesivir Runs out at the End of the Month. CNN. June 8, 2020.
- Siegel D.; Hui H. C.; Doerffler E.; Clarke M. O.; Chun K.; Zhang L.; Neville S.; Carra E.; Lew W.; Ross B.; et al. Discovery and Synthesis of a Phosphoramidate Prodrug of a Pyrrolo[2,1- f ][Triazin-4-Amino] Adenine C -Nucleoside (GS-5734) for the Treatment of Ebola and Emerging Viruses. J. Med. Chem. 2017, 60 (5), 1648–1661. 10.1021/acs.jmedchem.6b01594.
- Yan V. C.; Muller F. L.. Gilead Should Ditch Remdesivir and Focus on Its Simpler and Safer Ancestor. STAT. May 14, 2020.
- Warren T. K.; Jordan R.; Lo M. K.; Ray A. S.; Mackman R. L.; Soloveva V.; Siegel D.; Perron M.; Bannister R.; Hui H. C.; et al. Therapeutic Efficacy of the Small Molecule GS-5734 against Ebola Virus in Rhesus Monkeys. Nature 2016, 531, 381–385. 10.1038/nature17180.
- Sheahan T. P.; Sims A. C.; Graham R. L.; Menachery V. D.; Gralinski L. E.; Case J. B.; Leist S. R.; Pyrc K.; Feng J. Y.; Trantcheva I.; et al.Broad-Spectrum Antiviral GS-5734 Inhibits Both Epidemic and Zoonotic Coronaviruses. Sci. Transl. Med. 2017, 9 ( (396), ), eaal3653.10.1126/scitranslmed.aal3653
- Williamson B. N.; Feldmann F.; Schwarz B.; Meade-White K.; Porter D. P.; Schulz J.; Van Doremalen N.; Leighton I.; Yinda C. K.; Pérez-Pérez L.; et al. Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2. Nature 2020, 10.1038/s41586-020-2423-5.
- Gordon C. J.; Tchesnokov E. P.; Feng J. Y.; Porter D. P.; Gotte M. The Antiviral Compound Remdesivir Potently Inhibits RNA-Dependent RNA Polymerase from Middle East Respiratory Syndrome Coronavirus. J. Biol. Chem. 2020, 295, 4773.10.1074/jbc.AC120.013056.
- Alanazi A. S.; James E.; Mehellou Y. The ProTide Prodrug Technology: Where Next?. ACS Med. Chem. Lett. 2019, 10 (1), 2–5. 10.1021/acsmedchemlett.8b00586.
- Murakami E.; Wang T.; Babusis D.; Lepist E.-I.; Sauer D.; Park Y.; Vela J. E.; Shih R.; Birkus G.; Stefanidis D.; et al. Metabolism and Pharmacokinetics of the Anti-Hepatitis C Virus Nucleotide Prodrug GS-6620 Downloaded From. Antimicrob. Agents Chemother. 2014, 58, 1943–1951. 10.1128/AAC.02350-13.
- Bieganowski P.; Garrison P. N.; Hodawadekar S. C.; Faye G.; Barnes L. D.; Brenner C. Adenosine Monophosphoramidase Activity of Hint and Hnt1 Supports Function of Kin28, Ccl1, and Tfb3. J. Biol. Chem. 2002, 277 (13), 10852–10860. 10.1074/jbc.M111480200.
- Chou T.-F.; Baraniak J.; Kaczmarek R.; Zhou X.; Cheng J.; Ghosh B.; Wagner C. R. Phosphoramidate Pronucleotides: A Comparison of the Phosphoramidase Substrate Specificity of Human and Escherichia Coli Histidine Triad Nucleotide Binding Proteins. Mol. Pharmaceutics 2007, 4 (2), 208–217. 10.1021/mp060070y.
- Wichmann D.; Sperhake J.-P.; Lütgehetmann M.; Steurer S.; Edler C.; Heinemann A.; Heinrich F.; Mushumba H.; Kniep I.; Schröder A. S.; et al. Autopsy Findings and Venous Thromboembolism in Patients With COVID-19. Ann. Intern. Med. 2020, M20–2003. 10.7326/M20-2003.
- Beigel J. H.; Tomashek K. M.; Dodd L. E.; Mehta A. K.; Zingman B. S.; Kalil A. C.; Hohmann E.; Chu H. Y.; Luetkemeyer A.; Kline S.; et al. Remdesivir for the Treatment of Covid-19 — Preliminary Report. N. Engl. J. Med. 2020, 10.1056/NEJMoa2007764.
- Cooke A. M.; Baron D. N.. Section of Medicine with Section of Pathology-Serum Enzymes in Clinical Practice; 1963; Vol. 56.
- Testa B.; Mayer J. M.. Hydrolysis in Drug and Prodrug Metabolism: Chemistry, Biochemistry, and Enzymology; VHCA, 2003.
- Bahar F. G.; Ohura K.; Ogihara T.; Imai T. Species Difference of Esterase Expression and Hydrolase Activity in Plasma. J. Pharm. Sci. 2012, 101 (10), 3979–3988. 10.1002/jps.23258.
- Yong J. M. Origins of Serum Alkaline Phosphatase. J. Clin. Pathol. 1967, 20 (4), 647–653. 10.1136/jcp.20.4.647.
- Pruijssers A. J.; George A. S.; Schäfer A.; Leist S. R.; Gralinksi L. E.; Dinnon Iii K. H.; Yount B. L.; Agostini M. L.; Stevens L. J.; Chappell J. D.; et al. Remdesivir Potently Inhibits SARS-CoV-2 in Human Lung Cells and Chimeric SARS-CoV Expressing the SARS-CoV-2 RNA Polymerase in Mice. bioRxiv 2020, 10.1101/2020.04.27.064279.
- Lo M. K.; Jordan R.; Arvey A.; Sudhamsu J.; Shrivastava-Ranjan P.; Hotard A. L.; Flint M.; McMullan L. K.; Siegel D.; Clarke M. O.; et al. GS-5734 and Its Parent Nucleoside Analog Inhibit Filo-, Pneumo-, and Paramyxoviruses. Sci. Rep. 2017, 7 (1), 43395.10.1038/srep43395.
- Choy K.-T.; Wong A. Y.-L.; Kaewpreedee P.; Sia S. F.; Chen D.; Hui K. P. Y.; Chu D. K. W.; Chan M. C. W.; Cheung P. P.-H.; Huang X.; et al. Remdesivir, Lopinavir, Emetine, and Homoharringtonine Inhibit SARS-CoV-2 Replication in Vitro. Antiviral Res. 2020, 178, 104786.10.1016/j.antiviral.2020.104786.
- Pedersen N. C.; Perron M.; Bannasch M.; Montgomery E.; Murakami E.; Liepnieks M.; Liu H. Efficacy and Safety of the Nucleoside Analog GS-441524 for Treatment of Cats with Naturally Occurring Feline Infectious Peritoniti. J. Feline Med. Surg. 2019, 21 (4), 271–281. 10.1177/1098612X19825701.
- Murphy B. G.; Perron M.; Murakami E.; Bauer K.; Park Y.; Eckstrand C.; Liepnieks M.; Pedersen N. C. The Nucleoside Analog GS-441524 Strongly Inhibits Feline Infectious Peritonitis (FIP) Virus in Tissue Culture and Experimental Cat Infection Studies. Vet. Microbiol. 2018, 219, 226–233. 10.1016/j.vetmic.2018.04.026.
- Dickinson P. J.; Bannasch M.; Thomasy S. M.; Murthy V. D.; Vernau K. M.; Liepnieks M.; Montgomery E.; Knickelbein K. E.; Murphy B.; Pedersen N. C. Antiviral Treatment Using the Adenosine Nucleoside Analogue GS −441524 in Cats with Clinically Diagnosed Neurological Feline Infectious Peritonitis. J. Vet. Intern. Med. 2020, 10.1111/jvim.15780.
- Addie D.; Belák S.; Boucraut-Baralon C.; Egberink H.; Frymus T.; Gruffydd-Jones T.; Hartmann K.; Hosie M. J.; Lloret A.; Lutz H.; et al. Feline Infectious Peritonitis. ABCD Guidelines on Prevention and Management. J. Feline Med. Surg. 2009, 11 (7), 594–604. 10.1016/j.jfms.2009.05.008.
- Wang Y.; Zhang D.; Du G.; Du R.; Zhao J.; Jin Y.; Fu S.; Gao L.; Cheng Z.; Lu Q.; et al. Remdesivir in Adults with Severe COVID-19: A Randomised, Double-Blind, Placebo-Controlled, Multicentre Trial. Lancet 2020, 395 (10236), 1569–1578. 10.1016/S0140-6736(20)31022-9.
- Murphy B. G.; Perron M.; Murakami E.; Bauer K.; Park Y.; Eckstrand C.; Liepnieks M.; Pedersen N. C. The Nucleoside Analog GS-441524 Strongly Inhibits Feline Infectiousperitonitis (FIP) Virus in Tissue Culture and Experimental Cat Infection Studies. Vet. Microbiol. 2018, 219, 226–233. 10.1016/j.vetmic.2018.04.026.
- Agostini M. L.; Andres E. L.; Sims A. C.; Graham R. L.; Sheahan T. P.; Lu X.; Clinton Smith E.; Brett Case J.; Feng J. Y.; Jordan R.; et al. Coronavirus Susceptibility to the Antiviral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease Downloaded From. mBio 2018, 9 (2), ee00221–18. 10.1128/mBio.00221-18.
- Jarvis L. M.Scaling up Remdesivir amid the Coronavirus Crisis. C&EN. April 20, 2020.
- Williamson B. N.; Feldmann F.; Schwarz B.; Meade-White K.; Porter D. P.; Schulz J.; Doremalen N.; van Leighton I.; Yinda C. K.; Pérez-Pérez L.; et al. Clinical Benefit of Remdesivir in Rhesus Macaques Infected with SARS-CoV-2. bioRxiv 2020, 2020.04.15.043166.
- Cho A.; Saunders O. L.; Butler T.; Zhang L.; Xu J.; Vela J. E.; Feng J. Y.; Ray A. S.; Kim C. U. Synthesis and Antiviral Activity of a Series of 1′-Substituted 4-Aza-7,9-Dideazaadenosine C-Nucleosides. Bioorg. Med. Chem. Lett. 2012, 22 (8), 2705–2707. 10.1016/j.bmcl.2012.02.105.
Source: PubMed